-
ICD-10-CM Codes
›
-
C00-D49
Neoplasms
›
-
D37-D48
Neoplasms of uncertain behavior, polycythemia vera and myelodysplastic syndromes
›
-
D47-
Other neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue
›
-
2022 ICD-10-CM Diagnosis Code D47.0
2022 ICD-10-CM Diagnosis Code D47.0
Mast cell neoplasms of uncertain behavior
2016 2017 2018 - Converted to Parent Code 2019 2020 2021 2022 Non-Billable/Non-Specific Code
- D47.0 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail.
- The 2022 edition of ICD-10-CM D47.0 became effective on October 1, 2021.
- This is the American ICD-10-CM version of D47.0 - other international versions of ICD-10 D47.0 may differ.
Type 1 ExcludesType 1 Excludes Help
A type 1 excludes note is a pure excludes. It means "not coded here". A type 1 excludes note indicates that the code excluded should never be used at the same time as D47.0. A type 1 excludes note is for used for when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition.
- congenital cutaneous mastocytosis (
ICD-10-CM Diagnosis Code Q82.2
Congenital cutaneous mastocytosis
2016 2017 2018 - Revised Code 2019 2020 2021 2022 Billable/Specific Code POA Exempt
Applicable To- Congenital diffuse cutaneous mastocytosis
- Congenital maculopapular cutaneous mastocytosis
- Congenital urticaria pigmentosa
Type 1 Excludes- cutaneous mastocytosis NOS (D47.01)
- diffuse cutaneous mastocytosis (with onset after newborn period) (D47.01)
- malignant mastocytosis (C96.2-)
- systemic mastocytosis (D47.02)
- urticaria pigmentosa (non-congenital) (with onset after newborn period) (D47.01)
- histiocytic neoplasms of uncertain behavior (
ICD-10-CM Diagnosis Code D47.Z9
Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue
2016 2017 2018 2019 2020 2021 2022 Billable/Specific Code
Applicable To- Histiocytic tumors of uncertain behavior
- malignant mast cell neoplasm (
ICD-10-CM Diagnosis Code C96.2
Malignant mast cell neoplasm
2016 2017 2018 - Converted to Parent Code 2019 2020 2021 2022 Non-Billable/Non-Specific Code
Type 1 Excludes- indolent mastocytosis (D47.02)
- mast cell leukemia (C94.30)
- mastocytosis (congenital) (cutaneous) (Q82.2)
The following code(s) above
D47.0 contain annotation back-references
Annotation Back-References
In this context, annotation back-references refer to codes that contain:
- Applicable To annotations, or
- Code Also annotations, or
- Code First annotations, or
- Excludes1 annotations, or
- Excludes2 annotations, or
- Includes annotations, or
- Note annotations, or
- Use Additional annotations
that may be applicable to
D47.0:
- Mastocytoma
- Neoplasm of uncertain behavior, histiocytic or mas
- Neoplasm of uncertain behavior, histiocytic or mast cell
Clinical Information
- A form of systemic mastocytosis in which patients experience no pain. It is characterized by the multifocal mast cell filtrates, mostly in skin and bone marrow (<20% mast cells). It has a low cytomorphological grade.
- A growth or lump of mast cells (a type of white blood cell). Mast cell tumors can involve the skin, subcutaneous tissue, and muscle tissue.
- A heterogeneous group of disorders characterized by the abnormal growth and accumulation of mast cells in one or more organ systems. Recent data suggest that most variants of mastocytosis are clonal disorders. (who, 2001)
- A localized tumor composed of sheets of mast cells without atypia. It includes the cutaneous mastocytoma which involves the dermis and subcutaneous tissue, and the extracutaneous mastocytoma. Most cases of extracutaneous mastocytoma have been reported in the lung.
- A neoplasm composed of mast cells, for which the malignancy status has not been determined.
- An indolent mast cell neoplasm characterized by systemic infiltration of skin and internal organs by aggregates of neoplastic mast cells.
- An indolent mast cell neoplasm characterized by systemic infiltration of skin and internal organs by aggregates of neoplastic mast cells. There is no evidence of mast cell leukemia or clonal hematologic malignancy. Clinically, there is no evidence of palpable hepatomegaly and splenomegaly, malabsorption syndrome, or pathologic fractures.
- Nodular cutaneous mast cell infiltrate, which is usually present at birth or soon after as a solitary nodule, although three to four lesions may occur; lesions typical of urticaria pigmentosa may occur later.
Code History
- 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
- 2017 (effective 10/1/2016): No change
- 2018 (effective 10/1/2017): Deleted code
- 2018 (effective 10/1/2017): New code
- 2019 (effective 10/1/2018): No change
- 2020 (effective 10/1/2019): No change
- 2021 (effective 10/1/2020): No change
- 2022 (effective 10/1/2021): No change
ICD-10-CM Codes Adjacent To D47.0
D46.20 Refractory anemia with excess of blasts, unspecified
D46.21 Refractory anemia with excess of blasts 1
D46.22 Refractory anemia with excess of blasts 2
D46.A Refractory cytopenia with multilineage dysplasia
D46.B Refractory cytopenia with multilineage dysplasia and ring sideroblasts
D46.C Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality
D46.4 Refractory anemia, unspecified
D46.Z Other myelodysplastic syndromes
D46.9 Myelodysplastic syndrome, unspecified
D47 Other neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue
D47.0
Mast cell neoplasms of uncertain behavior
D47.09 Other mast cell neoplasms of uncertain behavior
D47.1 Chronic myeloproliferative disease
D47.2 Monoclonal gammopathy
D47.3 Essential (hemorrhagic) thrombocythemia
D47.Z Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue
D47.Z1 Post-transplant lymphoproliferative disorder (PTLD)
Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.
